Iradimed Corp. Files Definitive Proxy Materials

TL;DR

IRMD proxy filing is in, shareholders get to vote.

AI Summary

Iradimed Corp. is filing a Definitive Additional Materials proxy statement on May 3, 2024. This filing is related to the company's proxy materials and does not require a fee. The company is incorporated in DC and its fiscal year ends on December 31.

Why It Matters

This filing provides shareholders with important information regarding the company's upcoming meeting and voting matters, allowing them to participate in corporate governance.

Risk Assessment

Risk Level: low — This is a routine proxy filing and does not contain information that inherently increases risk for the company or its investors.

Key Players & Entities

• IRADIMED CORP (company) — Registrant
• 0000898432-24-000351 (filing_id) — Accession Number
• 20240503 (date) — Filing Date
• 20240502 (date) — Date as of Change
• 3841 (sic_code) — Standard Industrial Classification
• DC (jurisdiction) — State of Incorporation
• 1231 (fiscal_year_end) — Fiscal Year End
• 001-36534 (sec_file_number) — SEC File Number
• 4076778022 (phone_number) — Business Phone

FAQ

Filing Documents

• defa14a.htm (DEFA14A) — 14KB
• 0000898432-24-000351.txt ( ) — 15KB

From the Filing

SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 IRADIMED CORPORATION (Name of Registrant as Specified In Its Charter) N/A (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. Explanatory Note This supplement (this "Supplement") to IRADIMED CORPORATION's (the "Company") definitive proxy statement (the "Proxy Statement") filed with the U.S. Securities and Exchange Commission on April 29, 2024 for use at the 2024 Annual Meeting of Stockholders (the "Annual Meeting") is being filed to correct a certain inadvertent error. Except as specifically supplemented by the information contained in this Supplement, all information set forth in the Proxy Statement continues to apply and should be considered in voting your shares of Company common stock. On or about page 28 of the Proxy Statement, within the "Security Ownership of Certain Beneficial Owners and Management" section, the Company inadvertently indicated the incorrect date as it relates to ownership information reported in the aforementioned section. Instead of March 31, 2023, the date should have been April 22, 2024. Please note that the figures in the table do not need to be updated as they were reported as of April 22, 2024. Additional Information If you have already voted by Internet, telephone, or by mail, you do not need to take any action unless you wish to change your vote. Proxy voting instructions already returned by Company stockholders (via Internet, telephone, or by mail) will remain valid and will be voted at the Annual Meeting unless revoked. Important information regarding how to vote your shares and revoke proxies already cast is available in the Proxy

View Full Filing

View this DEFA14A filing on SEC EDGAR